SCHEMBL20385993

SCHEMBL20385993

Cc1cncnc1-c1ccc2cn[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 10/20 0.55
TGFBR1 P36897 4/20 0.52
FGFR2 P21802 4/20 0.49
FGFR3 P22607 2/20 0.49
ABL1 P00519 2/20 0.48
SRC P12931 2/20 0.48
KDR P35968 2/20 0.48
PIK3CD O00329 1/20 0.48
EGFR P00533 1/20 0.48
HCK P08631 1/20 0.48
PIK3CA P42336 1/20 0.48
PIK3CB P42338 1/20 0.48
MTOR P42345 1/20 0.48
PIK3CG P48736 1/20 0.48
EPHB4 P54760 1/20 0.48
PRKDC P78527 1/20 0.48
TGFBR2 P37173 1/20 0.46
BRAF P15056 1/20 0.45
DYRK1A Q13627 3/20 0.45
MAPK1 P28482 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21565626 0.85 ABL1 (0.51) FGFR1TGFBR1FGFR2FGFR3ABL1
SCHEMBL20386115 0.79 FGFR1 (0.51) FGFR1TGFBR1FGFR2FGFR3ABL1
SCHEMBL16805045 0.75 MAPK9 (0.61) ABL1SRCKDRPIK3CDEGFR
SCHEMBL21565627 0.75 ABL1 (0.50) FGFR1TGFBR1FGFR2FGFR3ABL1
SCHEMBL16806030 0.74 MAPT (0.41) FGFR1KDRDYRK1AMAPK1JAK2
SCHEMBL1318366 0.73 FGFR1 (0.55) FGFR1FGFR2FGFR3ABL1SRC
SCHEMBL15676773 0.73 TGFBR1 (0.61) FGFR1TGFBR1FGFR2FGFR3ABL1
SCHEMBL13115655 0.73 FGFR1 (0.71) FGFR1FGFR2FGFR3ABL1SRC
SCHEMBL20386108 0.72 FGFR1 (0.52) FGFR1TGFBR1FGFR2FGFR3ABL1
SCHEMBL28200925 0.72 FGFR1 (0.54) FGFR1FGFR2FGFR3ABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3568133-B1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE ETH ZUERICH (CH) 2023-12-13 EP disclosed
US-20210015793-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH ZURICH (CH) 2021-01-21 US disclosed
WO-2019179890-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH ZURICH (CH) 2019-09-26 WO disclosed
EP-3543231-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH Zurich (CH) 2019-09-25 EP disclosed
WO-2018130537-A1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE ETH Zürich (CH) 2018-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210015793-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES PPT1, SPTLC1, LPCAT1 FGFR1 4111/4885TGFBR1 4824/4885FGFR2 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.